Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation. Issue 47 (25th November 2022)

• Record Type: Journal Article
• Authors: Elsebaey, Mohamed A.; Elbedewy, Tamer A.; Elashry, Heba; Elrefaey, Waleed; Elshweikh, Samah A.; Elhadidy, Ahmed A.; Shalaby, Neveen A.; Elsokkary, Assem Mohamed; Elashtokhy, Hossam Eldin A.; Abo-Amer, Yousry Esam-Eldin; Abo-Elfetoh, Ashraf Rafat; Hassanien, Sharaf Elsayed Ali; Fouad, Amina; Abdellatif, Raghda Samir; Ismail, Amro Abdelaziz Mohammed
• Is Part Of: Medicine. Volume 101:Issue 47(2022)
• Page Start: e31962
• Publication Date: 2022-11-25
• Subjects: antiviral prophylaxis -- hepatitis B virus reactivation -- immunosuppressive therapy -- resolved hepatitis B virus -- viral monitoring; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000031962
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Risk of hepatitis B virus reactivation (HBVr) in patients with resolved HBV infection receiving immunosuppressive therapy has been a growing concern, particularly in the era of biological and targeted therapies. HBV monitoring versus antiviral prophylaxis against HBVr in those patients remains controversial. The aim of the study was to determine the incidence of HBVr and HBV-related hepatitis in resolved HBV patients who received immunosuppressive therapy with or without antiviral prophylaxis. This retrospective study included 64 patients with resolved HBV infection who received different regimens of immunosuppressive medications, with moderate risk of HBVr, for variable underlying diseases. Patients who had chronic HBV infection or other viral infections were excluded. Patients who received B-cell depleting therapies were ruled out. They were divided into 2 groups: group 1 included 31 patients who received immunosuppressive therapy without antiviral prophylaxis, and group 2 included 33 patients who received antiviral prophylaxis (entecavir) within 2 weeks of commencing the immunosuppressive therapy. HBVr, HBV-related hepatitis, and HBV-unrelated hepatitis were assessed along a 1-year duration. The overall HBVr incidence was 1.56% (1/64). This patient who had HBVr was seen in group 1. There were no significant differences between the 2 groups regarding the incidence of HBVr, HBV-related hepatitis, HBV-unrelated hepatitis, and immunosuppressive therapy interruption along a 1-year duration. Based on this retrospective study, close monitoring was equal to antiviral prophylaxis regarding the outcome of resolved HBV patients who received moderate risk immunosuppressive therapy. HBV treatment should commence once HBVr is confirmed.